Pascal Neuville, PhD

CEO, Domain Therapeutics – Board member

Pascal Neuville has a PhD in molecular biology from University of Strasbourg, France. He spent five years at the University of Geneva as a post doc and then as Assistant Professor. Pascal then joined Transgene SA as an R&D project leader.

From 2002 to 2008, he was CSO of Faust Pharmaceuticals SA, a drug discovery and development company in CNS.

He founded Domain Therapeutics in 2008 as CEO. From 2008 to 2010, Pascal was President of Alsace BioValley’s Board of Directors, the life science competitiveness cluster of Alsace, and continued as a board member from 2010 to 2014.

He is also a member of the investment committee of SATT Conectus Alsace, the private TTO of the University of Strasbourg and regional research institutions and sits on the boards of Axilum Robotics and Defymed.

Management team

Joël Crouzet, PhD

CEO & Chairman

Annegret Van der Aa, PhD

CSO & CDO

Stéphane Durant des Aulnois, MSc

CFO

Gerhard Müller, PhD

Head of Medicinal Chemistry

Hélène Asnagli, PhD

Head of Biology & Pharmacology

Scientific Advisor

Jean-Philippe Herbeuval, PhD

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Board Of Directors

David Main, BSc, MBA

President and CEO, Notch Therapeutics - Independent Board member

Joël Crouzet, PhD

CEO & Chairman

Pascal Neuville, PhD

CEO, Domain Therapeutics - Board member

Laurent Audoly, PhD

Founder & CEO of Parthenon Therapeutics - Board member

Thierry Laugel, PhD

Managing partner, Kurma Life Sciences Partners - Board member

Hadrien Bouchez

Principal, Kurma Life Sciences Partners - Board member

Aidan King, MBA, CFA

Managing Partner & Co-Founder, Fountain Healthcare Partners - Board member

Tania Papkovskaia, PhD

Senior Associate, Fountain Healthcare Partners - Board observer

Scientific Advisory Board

Jean-Philippe Herbeuval, PhD

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Piet Wigerinck, PhD

Chairman of the Scientific Advisory Board

Michel Bouvier, PhD

Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal

Martine Smit, PhD

Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam

Graeme Milligan, PhD

Gardiner Professor of Biochemistry, and Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow